Evidence map›Paper›PMID 36006736›Full record

ArticleThe Journal of clinical investigation2022

Mast cell-derived factor XIIIA contributes to sexual dimorphic defense against group B streptococcal infections.

Adrian M Piliponsky, Kavita Sharma, Phoenicia Quach, Alyssa Brokaw, Shayla Nguyen, Austyn Orvis, Siddhartha S Saha, Nyssa Becker Samanas, Ravin Seepersaud, Yu Ping Tang and 14 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Siglec-9 is an inhibitory receptor on human mast cells in vitro.The Journal of allergy and clinical immunology · 2023
    Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Adrian M PiliponskyCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Kavita SharmaCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Phoenicia QuachCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Alyssa BrokawDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Shayla NguyenCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Austyn OrvisCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Siddhartha S SahaCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Nyssa Becker SamanasCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Ravin SeepersaudCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Yu Ping TangDepartments of Large Animal Clinical Sciences, Physiology, Neuroscience Program, and College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Emily MackeyDepartments of Large Animal Clinical Sciences, Physiology, Neuroscience Program, and College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Gauri BhiseCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Claire GendrinCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Anna FurutaDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Albert J SeoCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Eric GugaCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Irina MiraldaCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
Michelle ColemanCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Erin L SweeneyCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Charlotte A BäumlPharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, Germany.
Diana ImhofPharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, Germany.
Jessica M SnyderDepartment of Comparative Medicine, University of Washington, Seattle, Washington, USA.
Adam J MoeserDepartments of Large Animal Clinical Sciences, Physiology, Neuroscience Program, and College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Lakshmi RajagopalDepartment of Pediatrics.
Infectious Disease Research Institute · USSeattle Children's Hospital · USMichigan State University · USUniversity of Bonn · DEUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Role of the hyaluronidase in GBS VirulenceR01AI133976 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADAMS WALDORF, KRISTINA M., RAJAGOPAL, LAKSHMI · 2017 to 2021
$4.5M
Immune Control of Group B Streptococcal PlacentalR01AI145890 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADAMS WALDORF, KRISTINA M., RAJAGOPAL, LAKSHMI · 2019 to 2023
$4.4M
Neutralizing the GBS hemolytic lipid toxinR01AI167421 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI RAJAGOPAL, LAKSHMI · 2022 to 2025
$4.1M
Neuro-Immune Mechanisms in Early Life Stress-Induced Gastrointestinal DiseaseR01HD072968 · NICHD · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI MOESER, ADAM, ROBISON, ALFRED J · 2013 to 2023
$3.8M
FXIIIA production by mast cells for innate immunityR01AI152268 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI PILIPONSKY, ADRIAN M, RAJAGOPAL, LAKSHMI · 2020 to 2024
$3.7M
INTERDISCIPLINARY PROGRAM IN BACTERIAL PATHOGENESIST32AI055396 · NIAID · UNIVERSITY OF WASHINGTON · PI FANG, FERRIC C · 2003 to 2019
$2.8M
Origins of Sex Differences in Mast Cell Associated Immune DiseasesR21AI140413 · NIAID · MICHIGAN STATE UNIVERSITY · PI JORDAN, CYNTHIA L, MOESER, ADAM · 2018 to 2019
$412k
NCI NIH HHS P30 CA015704NIAID NIH HHS R01 AI133976NIAID NIH HHS R01 AI145890NIAID NIH HHS R01 AI152268NIAID NIH HHS R01 AI167421NIAID NIH HHS R21 AI140413NIAID NIH HHS T32 AI007509NIAID NIH HHS T32 AI055396NICHD NIH HHS R01 HD072968
6 · The paper itself

Abstract

Invasive bacterial infections remain a major cause of human morbidity. Group B streptococcus (GBS) are Gram-positive bacteria that cause invasive infections in humans. Here, we show that factor XIIIA-deficient (FXIIIA-deficient) female mice exhibited significantly increased susceptibility to GBS infections. Additionally, female WT mice had increased levels of FXIIIA and were more resistant to GBS infection compared with isogenic male mice. We observed that administration of exogenous FXIIIA to male mice increased host resistance to GBS infection. Conversely, administration of a FXIIIA transglutaminase inhibitor to female mice decreased host resistance to GBS infection. Interestingly, male gonadectomized mice exhibited decreased sensitivity to GBS infection, suggesting a role for gonadal androgens in host susceptibility. FXIIIA promoted GBS entrapment within fibrin clots by crosslinking fibronectin with ScpB, a fibronectin-binding GBS surface protein. Thus, ScpB-deficient GBS exhibited decreased entrapment within fibrin clots in vitro and increased dissemination during systemic infections. Finally, using mice in which FXIIIA expression was depleted in mast cells, we observed that mast cell-derived FXIIIA contributes to host defense against GBS infection. Our studies provide insights into the effects of sexual dimorphism and mast cells on FXIIIA expression and its interactions with GBS adhesins that mediate bacterial dissemination and pathogenesis.

Indexed as

Factor XIIIaStreptococcal InfectionsAndrogensAnimalsFemaleFibrinFibronectinsHumansMaleMast CellsMiceStreptococcus agalactiaeTransglutaminasesAndrogensFactor XIIIaFibrinFibronectinsTransglutaminasesBacterial infectionsCell BiologyCoagulationInfectious diseaseMast cells

Identifiers

PMID36006736
PMCPMC9566924
OpenAlexW4293105256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.